It has recently been reported that betahistine and OLZ co-treatment ameliorated OLZ-induced weight gain and dyslipidemia through the modulation of histaminergic, AMPKα–SREBP1, and PPARγ-dependent pathways [42]. Here, SREBF1 is linked to metabolic syndrome.